The global RNA interference (RNAi) market accounted for USD 1.23 billion in 2023 and is expected to reach USD 6.51 billion by 2034 with a CAGR of 16.33% during the forecast period 2024-2034. The market will grow due to rising investments in RNAi research and development, increasing demand for RNAi therapeutics, improvements in RNAi delivery technologies, regulatory support for RNAi therapeutics, and strategic alliances and collaborations.
The potential of RNAi-based medicines to treat a variety of diseases, including as cancer, genetic disorders, infectious diseases, and rare illnesses, has drawn attention to them. RNA interference (RNAi) presents a viable target for medication development since it can specifically target genes that cause disease while protecting healthy cells. For instance, Dicerna Pharmaceuticals gave updates in January 2024 regarding their partnership with Novo Nordisk to create RNAi therapies for cardiometabolic illnesses associated with the liver.
By type, the siRNA segment accounted for the highest revenue-grossing segment in the global RNA interference (RNAi) market in 2023 owing to the high specificity, potency, and versatility of siRNA molecules in targeting disease-causing genes, driving their widespread adoption in therapeutic and research applications. For instance, in January 2024, Alnylam Pharmaceuticals declared that patient enrolment in the HELIOS-A Phase 3 trial of vutrisiran for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) was completed. Additionally, the miRNA segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing understanding of the role of microRNAs in gene regulation and disease pathogenesis, coupled with advancements in delivery technologies enhancing their therapeutic potential.
By application, the drug discovery and development segment accounted for the highest revenue-grossing segment in the global RNA interference (RNAi) market in 2023 owing to the growing demand for RNAi technology in target validation, lead optimization, and preclinical studies, accelerating drug discovery timelines and reducing development costs. For instance, Arrowhead Pharmaceuticals announced in November 2023 that individuals with familial chylomicronemia syndrome (FCS) would be enrolled in a Phase 2/3 research trial of ARO-APOC3. Additionally, the therapeutics segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding pipeline of RNAi-based drugs targeting various diseases, advancements in delivery systems enhancing efficacy, and increasing regulatory approvals paving the way for commercialization.
By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global RNA interference (RNAi) market in 2023 owing to the significant investments in RNAi research and development, robust pipeline of RNAi therapeutics, and strategic partnerships driving innovation and commercialization efforts. For instance, Novartis expanded its pipeline and enhanced its RNAi expertise when it purchased Quark Pharmaceuticals in November 2023. Additionally, the contract research organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing outsourcing of RNAi-related services by pharmaceutical and biotechnology companies, expanding demand for RNAi-based drug development and screening services, and advancements in RNAi technology driving research collaborations.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of a mature biotechnology and pharmaceutical industry, strong research infrastructure, favorable regulatory environment, and high investments in RNA interference (RNAi) research and development. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of RNA interference (RNAi) technology in emerging economies, expanding biotechnology and pharmaceutical sectors, and rising investments in healthcare research and development. For instance, Ionis Pharmaceuticals stated in December 2023 that vupanorsen (ION449) would be the subject of a Phase 3 clinical trial for people with familial chylomicronemia syndrome (FCS).
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The potential of RNAi-based medicines to treat a variety of diseases, including as cancer, genetic disorders, infectious diseases, and rare illnesses, has drawn attention to them. RNA interference (RNAi) presents a viable target for medication development since it can specifically target genes that cause disease while protecting healthy cells. For instance, Dicerna Pharmaceuticals gave updates in January 2024 regarding their partnership with Novo Nordisk to create RNAi therapies for cardiometabolic illnesses associated with the liver.
By type, the siRNA segment accounted for the highest revenue-grossing segment in the global RNA interference (RNAi) market in 2023 owing to the high specificity, potency, and versatility of siRNA molecules in targeting disease-causing genes, driving their widespread adoption in therapeutic and research applications. For instance, in January 2024, Alnylam Pharmaceuticals declared that patient enrolment in the HELIOS-A Phase 3 trial of vutrisiran for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) was completed. Additionally, the miRNA segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing understanding of the role of microRNAs in gene regulation and disease pathogenesis, coupled with advancements in delivery technologies enhancing their therapeutic potential.
By application, the drug discovery and development segment accounted for the highest revenue-grossing segment in the global RNA interference (RNAi) market in 2023 owing to the growing demand for RNAi technology in target validation, lead optimization, and preclinical studies, accelerating drug discovery timelines and reducing development costs. For instance, Arrowhead Pharmaceuticals announced in November 2023 that individuals with familial chylomicronemia syndrome (FCS) would be enrolled in a Phase 2/3 research trial of ARO-APOC3. Additionally, the therapeutics segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding pipeline of RNAi-based drugs targeting various diseases, advancements in delivery systems enhancing efficacy, and increasing regulatory approvals paving the way for commercialization.
By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global RNA interference (RNAi) market in 2023 owing to the significant investments in RNAi research and development, robust pipeline of RNAi therapeutics, and strategic partnerships driving innovation and commercialization efforts. For instance, Novartis expanded its pipeline and enhanced its RNAi expertise when it purchased Quark Pharmaceuticals in November 2023. Additionally, the contract research organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing outsourcing of RNAi-related services by pharmaceutical and biotechnology companies, expanding demand for RNAi-based drug development and screening services, and advancements in RNAi technology driving research collaborations.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of a mature biotechnology and pharmaceutical industry, strong research infrastructure, favorable regulatory environment, and high investments in RNA interference (RNAi) research and development. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of RNA interference (RNAi) technology in emerging economies, expanding biotechnology and pharmaceutical sectors, and rising investments in healthcare research and development. For instance, Ionis Pharmaceuticals stated in December 2023 that vupanorsen (ION449) would be the subject of a Phase 3 clinical trial for people with familial chylomicronemia syndrome (FCS).
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: RNA Interference (RNAi) Market Report 2023 - 2034
RNA Interference (RNAi) Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- dsRNA
- siRNA
- miRNA
RNA Interference (RNAi) Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Drug Discovery and Development
- Therapeutics
- Agricultural Crop Modifications
- Others
RNA Interference (RNAi) Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academia and Research Centers
- Others
RNA Interference (RNAi) Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. RNA Interference (RNAi) Market: Type Estimates & Trend Analysis
8. RNA Interference (RNAi) Market: Application Estimates & Trend Analysis
9. RNA Interference (RNAi) Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America RNA Interference (RNAi) Market
12. Europe Global RNA Interference (RNAi) Market
13. Asia Pacific Global RNA Interference (RNAi) Market
14. Latin America Global RNA Interference (RNAi) Market
15. MEA Global RNA Interference (RNAi) Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Alnylam Pharmaceuticals
- Arrowhead Pharmaceuticals
- Dicerna Pharmaceuticals
- Quark Pharmaceuticals
- Silence Therapeutics
- Ionis Pharmaceuticals
- Arcturus Therapeutics
- Sirnaomics Inc.
- Benitec Biopharma
- miRagen Therapeutics
- Olix Pharmaceuticals
- miRecule Inc.
- RXi Pharmaceuticals
- Sylentis
- Tacere Therapeutics.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.23 Billion |
| Forecasted Market Value ( USD | $ 6.51 Billion |
| Compound Annual Growth Rate | 16.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
